Cargando…

MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2

Detalles Bibliográficos
Autores principales:	Tian, Faqing, Zhan, Yong, Zhu, Wei, Li, Juheng, Tang, Meiqin, Chen, Xiaohui, Jiang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713415/ https://www.ncbi.nlm.nih.gov/pubmed/31432126 http://dx.doi.org/10.3892/ijmm.2019.4297

Ejemplares similares

The antibiotic chloramphenicol may be an effective new agent for inhibiting the growth of multiple myeloma
por: Tian, Faqing, et al.
Publicado: (2016)

Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2–myeloma cell interaction
por: Tian, Faqing, et al.
Publicado: (2019)

Long intergenic non-protein coding RNA 152 promotes multiple myeloma progression by negatively regulating microRNA-497
por: Yu, Tianhua, et al.
Publicado: (2022)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Regulation of microRNA-497 expression in human cancer
por: Luo, Guanshui, et al.
Publicado: (2021)

Corrigendum to “Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc” [Redox Biol. 13 (2017) 482–497]
por: Yang, Shikun, et al.
Publicado: (2019)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1
por: Ye, Cheng-Yu, et al.
Publicado: (2018)

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
por: Ryan, J, et al.
Publicado: (2012)

Circular RNA Profiling Reveals That circRNA_104433 Regulates Cell Growth by Targeting miR-497-5p in Gastric Cancer [Corrigendum]
Publicado: (2020)

Transcriptome dynamics of the microRNA inhibition response
por: Wen, Jiayu, et al.
Publicado: (2016)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Corrigendum to “Exercise Training Restores Cardiac MicroRNA-1 and MicroRNA-29c to Nonpathological Levels in Obese Rats”
por: Silveira, André C., et al.
Publicado: (2018)

MicroRNA-497 Reduction and Increase of Its Family Member MicroRNA-424 Lead to Dysregulation of Multiple Inflammation Related Genes in Synovial Fibroblasts With Rheumatoid Arthritis
por: Wang, Si, et al.
Publicado: (2021)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Corrigendum to: Microfluidic enrichment of plasma cells improves treatment of multiple myeloma
por: Zeng, Yunjing, et al.
Publicado: (2021)

Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?
por: Ballabio, E, et al.
Publicado: (2012)

MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase
por: Rodrigues-Junior, Dorival Mendes, et al.
Publicado: (2021)

MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4
por: Xiao, Yimin, et al.
Publicado: (2016)

Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
por: Sanchez, W Y, et al.
Publicado: (2013)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2011)

A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles
por: Guo, Jing, et al.
Publicado: (2021)

Human peripheral blood-derived exosomes for microRNA delivery
por: Kang, Ji-Young, et al.
Publicado: (2019)

Corrigendum to “Biomarker MicroRNAs for Diagnosis of Oral Squamous Cell Carcinoma Identified Based on Gene Expression Data and MicroRNA-mRNA Network Analysis”
por: Zhang, Hui, et al.
Publicado: (2017)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

MicroRNA-218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2
por: Mu, Lijun, et al.
Publicado: (2022)

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma
por: Wei, Daolin, et al.
Publicado: (2016)

MicroRNA-152 suppresses cisplatin resistance in A549 cells
por: Zhao, Wenfei, et al.
Publicado: (2020)

MirGeneDB 2.0: the metazoan microRNA complement
por: Fromm, Bastian, et al.
Publicado: (2020)

Expression of microRNA-497 and its prognostic significance in human breast cancer
por: Wang, Shaohua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hggp9o73hg9nrqts23grd4voe5